The future of cancer neuroscience

Episode Summary

Executive Summary: This episode explores Michelle Monje’s research on cancer neuroscience: how childhood gliomas exploit neuron, glial, and immune-cell signaling to grow, invade, and resist treatment. Monje explains that brain tumors can form synapses with neurons, hijack activity-dependent growth signals, and reshape neural circuits. She also describes promising early results from GD2-targeted CAR T-cell therapy and the next step of combining immunotherapy with neuronal modulation.

Main Topics: Origin of cancer neuroscience research (Priority: 5/5): Monje describes clinical observations that pushed her to ask whether brain activity and neural development influence glioma behavior, especially the consistent age-and-location patterns of pediatric tumors. Core brain cell types and glial biology (Priority: 4/5): The discussion reviews neurons, astrocytes, oligodendrocytes, and oligodendrocyte precursor cells, emphasizing how glia support signaling, insulation, plasticity, and metabolic function. Why pediatric gliomas are uniquely devastating (Priority: 5/5): Monje explains diffuse midline glioma/DIPG and related gliomas as highly aggressive childhood cancers arising in the brainstem, thalamus, and spinal cord, with near-universal fatality. Neuron-to-cancer communication (Priority: 5/5): The episode details how brain activity promotes tumor growth through activity-regulated factors and direct synaptic integration, showing that neurons actively feed tumor progression. CAR T-cell therapy for diffuse midline glioma (Priority: 5/5): Monje outlines a GD2-targeted CAR T strategy that cured mouse models and produced early human responses, including major tumor shrinkage and one complete response. Brain immune environment and delivery routes (Priority: 4/5): The conversation corrects the older idea of brain immune privilege and describes how CAR T cells can reach tumors via blood or direct ventricular delivery. Future combination therapies (Priority: 5/5): The next frontier is combining CAR T cells with strategies that reduce neuronal feed-me signals and improve immune-cell performance inside the nervous system.

Key Arguments: Brain tumors are not isolated masses; they are embedded in and dependent on neural circuitry. Neuron activity can directly accelerate glioma growth, proving that the nervous system actively contributes to tumor progression. Glioma cells form synapse-like connections with neurons, creating direct electrical communication that supports invasion and therapy resistance. The cancer also alters neurons and circuits indirectly, increasing excitability and seizure risk while reshaping the tumor microenvironment. GD2 is a useful therapeutic target because it is highly and uniformly expressed on diffuse midline glioma cells and is suitable for CAR T-cell recognition. CAR T therapy has already shown striking early human benefit, but durable control will likely require pairing immune therapy with neuronal pathway blockade. A combination strategy may both slow tumor growth and remove nervous-system barriers to immune-cell function.

Data Points: Year Stanford podcast launched: 2017 - Russ Altman notes the show began in 2017 as a forum for campus research discussions. Duration of Monje’s lab work on the question: about 15 years - She says she began pursuing neural influences on cancer after starting her laboratory roughly 15 years ago. Pediatric disease impact: leading cause of cancer-related death in kids - Diffuse midline glioma/DIPG is described as the leading cause of cancer-related death in children. Clinical response in early trial: wheelchair-bound to walking - In the GD2 CAR T trial, some patients showed dramatic functional improvement. Complete response cases: 1 patient in the first dozen or so - One early trial participant had complete tumor disappearance. Time in remission for complete responder: over 4 years - The complete responder remains tumor-free and thriving more than four years after first therapy. Tumor reduction in major responders: >90% - Several patients had major responses with more than 90% tumor reduction before later progression.

Pivotal Quotes: "the cancer actually needs the function of the nervous system" — Michelle Monje: Explaining why gliomas behave differently from typical mass lesions and why neuronal activity matters. "they're synaptically integrating into the brain" — Michelle Monje: Describing how glioma cells form direct neuron-to-cancer communication channels. "It was really clear, clear clinical benefit" — Michelle Monje: Reflecting on early CAR T-cell trial responses in patients with diffuse midline glioma.

Implications: The episode suggests brain cancer treatment may require targeting both tumor cells and the neural circuits that sustain them. It points to a future of combination therapies blending immunotherapy with neuroscience-based interventions.